Current Diabetes Reports

, Volume 8, Issue 6, pp 464–469

Vitamin D and diabetic nephropathy

Article

Abstract

Diabetic nephropathy (DN) is the most common renal complication of diabetes mellitus and a leading cause of end-stage renal disease. The renin-angiotensin system (RAS) is a major mediator of progressive renal injury in DN, and RAS inhibitors have been used as the mainstay treatment for DN. One major problem limiting the efficacy of the RAS inhibitors is the compensatory renin increase caused by disruption of renin feedback inhibition. Vitamin D negatively regulates the RAS by suppressing renin expression and thus plays a renoprotective role in DN. Diabetic vitamin D receptor-null mutant mice develop more severe renal injuries because of more robust RAS activation. Combination therapy with an RAS inhibitor and a vitamin D analogue markedly ameliorates renal injuries due to blockade of the compensatory renin increase by the analogue. These most recent data demonstrate that vitamin D and its analogues have renoprotective and therapeutic potentials in DN through targeting the RAS.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Centers for Disease Control and Prevention: National diabetes fact sheet general information and national estimates on diabetes in the United States, 2007. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. 2007. Accessed August 28, 2008.
  2. 2.
    Cooper ME: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998, 352:213–219.PubMedCrossRefGoogle Scholar
  3. 3.
    Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813–820.PubMedCrossRefGoogle Scholar
  4. 4.
    Carey RM, Siragy HM: The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003, 14:274–281.PubMedCrossRefGoogle Scholar
  5. 5.
    Ziyadeh FN: Mediators of diabetic renal disease: the case for TGF-beta as the major mediator. J Am Soc Nephrol 2004, 15(Suppl 1):S55–S57.PubMedCrossRefGoogle Scholar
  6. 6.
    Furuta T, Saito T, Ootaka T, et al.: The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993, 21:480–485.PubMedGoogle Scholar
  7. 7.
    Lavoie JL, Sigmund CD: Minireview: overview of the reninangiotensin system-an endocrine and paracrine system. Endocrinology 2003, 144:2179–2183.PubMedCrossRefGoogle Scholar
  8. 8.
    Paul M, Poyan Mehr A, Kreutz R: Physiology of local renin-angiotensin systems. Physiol Rev 2006, 86:747–803.PubMedCrossRefGoogle Scholar
  9. 9.
    Chan JC, Ko GT, Leung DH, et al.: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000, 57:590–600.PubMedCrossRefGoogle Scholar
  10. 10.
    Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.PubMedCrossRefGoogle Scholar
  11. 11.
    Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.PubMedCrossRefGoogle Scholar
  12. 12.
    Andersen S, Tarnow L, Rossing P, et al.: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000, 57:601–606.PubMedCrossRefGoogle Scholar
  13. 13.
    Price DA, Porter LE, Gordon M, et al.: The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999, 10:2382–2391.PubMedGoogle Scholar
  14. 14.
    Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002, 39:129–134.PubMedCrossRefGoogle Scholar
  15. 15.
    Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993, 265:F477–F486.PubMedGoogle Scholar
  16. 16.
    Vidotti DB, Casarini DE, Cristovam PC, et al.: High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004, 286:F1039–F1045.PubMedCrossRefGoogle Scholar
  17. 17.
    Yoo TH, Li JJ, Kim JJ, et al.: Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007, 71:1019–1027.PubMedCrossRefGoogle Scholar
  18. 18.
    Kelly DJ, Wilkinson-Berka JL, Allen TJ, et al.: A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 1998, 54:343–352.PubMedCrossRefGoogle Scholar
  19. 19.
    Hoffmann S, Podlich D, Hahnel B, et al.: Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004, 15:1475–1487.PubMedCrossRefGoogle Scholar
  20. 20.
    Schiffer M, Bitzer M, Roberts IS, et al.: Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001, 108:807–816.PubMedGoogle Scholar
  21. 21.
    Roestenberg P, van Nieuwenhoven FA, Joles JA, et al.: Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2006, 290:F1344–F1354.PubMedCrossRefGoogle Scholar
  22. 22.
    Ha H, Yu MR, Choi YJ, et al.: Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 2002, 13:894–902.PubMedGoogle Scholar
  23. 23.
    Yamagishi S, Inagaki Y, Okamoto T, et al.: Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002, 277:20309–20315.PubMedCrossRefGoogle Scholar
  24. 24.
    Holick MF: Vitamin D: photobiology, metabolism, mechanism of action, and clinical application. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 3. Edited by Favus MJ. Philadelphia: Lippincott-Raven; 1996:74–81.Google Scholar
  25. 25.
    Haussler MR, Whitfield GK, Haussler CA, et al.: The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998, 13:325–349.PubMedCrossRefGoogle Scholar
  26. 26.
    Nagpal S, Na S, Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26:662–687.PubMedCrossRefGoogle Scholar
  27. 27.
    Li YC, Qiao G, Uskokovic M, et al.: Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004, 89-90:387–392.PubMedCrossRefGoogle Scholar
  28. 28.
    Li YC, Kong J, Wei M, et al.: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110:229–238.PubMedGoogle Scholar
  29. 29.
    Zhou CL, Lu FX, Cao KX, et al.: Calcium-independent and 1,25(OH)(2)D(3)-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 2008, 74:170–179.PubMedCrossRefGoogle Scholar
  30. 30.
    Xiang W, Kong J, Chen S, et al.: Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005, 288:E125–E132.PubMedCrossRefGoogle Scholar
  31. 31.
    Kong J, Qiao G, Zhang Z, et al.: Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int 2008 (in press).Google Scholar
  32. 32.
    Yuan W, Pan W, Kong J, et al.: 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007, 282:29821–29830.PubMedCrossRefGoogle Scholar
  33. 33.
    Qiao G, Kong J, Uskokovic M, Li YC: Analogs of 1alpha,25-dihydroxyvitamin D3 as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 2005, 96:59–66.PubMedCrossRefGoogle Scholar
  34. 34.
    Fryer RM, Rakestraw PA, Nakane M, et al.: Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 2007, 106:p76–p81.PubMedCrossRefGoogle Scholar
  35. 35.
    Levin A, Bakris GL, Molitch M, et al.: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71:31–38.PubMedCrossRefGoogle Scholar
  36. 36.
    Levin A, Li YC: Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005, 68:1973–1981.PubMedCrossRefGoogle Scholar
  37. 37.
    Shoben AB, Rudser KD, de Boer IH, et al.: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008, 19:1613–1619.PubMedCrossRefGoogle Scholar
  38. 38.
    Shoji T, Shinohara K, Kimoto E, et al.: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004, 19:179–184.PubMedCrossRefGoogle Scholar
  39. 39.
    Teng M, Wolf M, Ofsthun MN, et al.: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16:1115–1125.PubMedCrossRefGoogle Scholar
  40. 40.
    Kuhlmann A, Haas CS, Gross ML, et al.: 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004, 286:F526–F533.PubMedCrossRefGoogle Scholar
  41. 41.
    Makibayashi K, Tatematsu M, Hirata M, et al.: A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001, 158:1733–1741.PubMedGoogle Scholar
  42. 42.
    Zhang Z, Sun L, Wang Y, et al.: Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008, 73:163–171.PubMedCrossRefGoogle Scholar
  43. 43.
    Zhang Z, Yuan W, Sun L, et al.: 1,25-Dihydroxyvitamin D(3) targeting of NF-kappaB suppresses high glucoseinduced MCP-1 expression in mesangial cells. Kidney Int 2007, 72:193–201.PubMedCrossRefGoogle Scholar
  44. 44.
    Gross JL, de Azevedo MJ, Silveiro SP, et al.: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164–176.PubMedCrossRefGoogle Scholar
  45. 45.
    Izuhara Y, Nangaku M, Inagi R, et al.: Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005, 16:3631–3641.PubMedCrossRefGoogle Scholar
  46. 46.
    Eijkelkamp WB, Zhang Z, Remuzzi G, et al.: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007, 18:1540–1546.PubMedCrossRefGoogle Scholar
  47. 47.
    Parving HH, Persson F, Lewis JB, et al.: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446.PubMedCrossRefGoogle Scholar
  48. 48.
    Muller DN, Luft FC: Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006, 1:221–228.PubMedCrossRefGoogle Scholar
  49. 49.
    Li YC: Inhibition of renin: an updated review of the development of renin inhibitors. Curr Opin Investig Drugs 2007, 8:750–757.PubMedGoogle Scholar
  50. 50.
    Borghi C, Boschi S, Ambrosioni E, et al.: Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993, 33:40–45.PubMedGoogle Scholar
  51. 51.
    Roig E, Perez-Villa F, Morales M, et al.: Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000, 21:53–57.PubMedCrossRefGoogle Scholar
  52. 52.
    Azizi M, Menard J, Bissery A, et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004, 15:3126–3133.PubMedCrossRefGoogle Scholar
  53. 53.
    Zhang Z, Zhang Y, Ning G, et al.: Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008 (in press).Google Scholar
  54. 54.
    Shankland SJ: The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006, 69:2131–2147.PubMedCrossRefGoogle Scholar
  55. 55.
    Kawachi H, Miyauchi N, Suzuki K, et al.: Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton) 2006, 11:274–281.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Department of MedicineThe University of ChicagoChicagoUSA

Personalised recommendations